Lamivudine & Zidovudine Tablets 150mg + 300mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 150mg + 300mg

Reference Brands: Combivir (USA/EU)

Category: Anti Viral

Lamivudine 150 mg and zidovudine 300 mg tablets, a twice-daily NRTI backbone now used mainly in second-line HIV regimens. For national HIV programmes, tender buyers, hospitals and licensed importers.

Product Description:

This tablet combines two nucleoside reverse transcriptase inhibitors, lamivudine 150 mg and zidovudine 300 mg. Both are taken up into cells, converted to triphosphates and built into viral DNA, where they stop the chain and block HIV replication. Zidovudine was the first antiretroviral, and this pairing served as a standard NRTI backbone for many years. The film-coated tablet gives a full adult dose of both drugs, taken twice daily, always with a third antiretroviral.

WHO guidelines have moved first-line treatment to dolutegravir with tenofovir and lamivudine or emtricitabine, so this backbone is now used mostly in second-line regimens after tenofovir failure, and in some children. It is taken with or without food. Zidovudine suppresses bone marrow, so haemoglobin and neutrophil counts are checked, and severe anaemia or neutropenia rules it out. Nausea, headache, nail pigmentation, lipoatrophy and lactic acidosis can occur. Stavudine must not be combined with it. Stopping lamivudine in hepatitis B co-infection can trigger a hepatitis flare.

Sourcing notes. National HIV programmes and donor-funded tenders usually require WHO prequalification or approval by a stringent regulatory authority, so ask which applies and for the reference number. Each batch needs a CoA with assay, dissolution and related substances for lamivudine and zidovudine; ask too for the GMP certificate, a CoPP and the bioequivalence report. Tablets come in HDPE bottles of 60 with desiccant or in blisters, at room temperature with no cold chain, with zone IVb stability data. Check shelf life on arrival against programme rules.